What to buy now?
With my sale of a portion of my Google holdings, I have some cash burning a hole in my pocket ... so what should I buy?
I have a few new companies that I'm interested in, all of which are a bit off their highs. Chief among these are Blackboard (BBBB) and Irobot (IRBT). And I've also been looking lately at Viisage (VISG), the security/biometrics company that has been going through some severe volatility and is close to consummating a merger with one of it's major competitors (something that VISG has in common with BBBB, actually).
And I've also been looking at a few of my holdings that appear to be very nicely priced right now. CV Therapeutics (CVTX) has been in the doldrums for months, and it appears that folks are not nearly as optimistic about Ranexa as they were last year. It may be that over the next month or two before we hear anything substantive about Ranexa sales and the MERLIN followup study for label expansion are the final opportunity for buying shares on the cheap.
Or it might be that Ranexa never moves beyond being a marginal last-resort drug for Chronic angina, in which case the shares would still be overpriced now. Given the number of people with angina problems, I'm inclined to lean in favor of any drug that offers a new method of treatment -- as Ranexa does, and with their approval for limited use this is the first new treatment for Angina in decades. I've written about limitations for existing angina treatments before, which also may eventually help to spur Ranexa sales.
And Lionsgate (LGF) looks very reasonably priced here as well. Analysts seem skeptical of their movie slate for this year, but I wouldn't be surprised to see Starbucks help propel Akeelah and the Bee into a great box office success, and we can expect Saw III to make for a bloody and lucrative Halloween ... and I continue to think that the increasing focus on the value of film and tv libraries will boost the price of LGF this year, whether or not they actually get any takeover bids.
Finally, Cemex (CX) has climbed somewhat since I purchased shares, but given the worldwide boom in infrastructure and the current and near-future highway spending in the US I think this dominant international cement company has a great future. I'd like to get it at a lower price, but I think the trends in their businesses around the world are almost all in their favor. Exposure to Mexico is a big plus, in my opinion, but most of Cemex's business is actually outside their home country. I also do like, incidentally, Fomento Economico Mexicano (FMX) (AKA FEMSA) as another potential Mexican play on beer, Coke bottling, and convenience stores ... I'd prefer to look at a smaller cap company, but if those shares come down a little I'll be looking at them much more closely.
If you have any opinions about where I ought to be investing now, I'd love to hear them.
I have a few new companies that I'm interested in, all of which are a bit off their highs. Chief among these are Blackboard (BBBB) and Irobot (IRBT). And I've also been looking lately at Viisage (VISG), the security/biometrics company that has been going through some severe volatility and is close to consummating a merger with one of it's major competitors (something that VISG has in common with BBBB, actually).
And I've also been looking at a few of my holdings that appear to be very nicely priced right now. CV Therapeutics (CVTX) has been in the doldrums for months, and it appears that folks are not nearly as optimistic about Ranexa as they were last year. It may be that over the next month or two before we hear anything substantive about Ranexa sales and the MERLIN followup study for label expansion are the final opportunity for buying shares on the cheap.
Or it might be that Ranexa never moves beyond being a marginal last-resort drug for Chronic angina, in which case the shares would still be overpriced now. Given the number of people with angina problems, I'm inclined to lean in favor of any drug that offers a new method of treatment -- as Ranexa does, and with their approval for limited use this is the first new treatment for Angina in decades. I've written about limitations for existing angina treatments before, which also may eventually help to spur Ranexa sales.
And Lionsgate (LGF) looks very reasonably priced here as well. Analysts seem skeptical of their movie slate for this year, but I wouldn't be surprised to see Starbucks help propel Akeelah and the Bee into a great box office success, and we can expect Saw III to make for a bloody and lucrative Halloween ... and I continue to think that the increasing focus on the value of film and tv libraries will boost the price of LGF this year, whether or not they actually get any takeover bids.
Finally, Cemex (CX) has climbed somewhat since I purchased shares, but given the worldwide boom in infrastructure and the current and near-future highway spending in the US I think this dominant international cement company has a great future. I'd like to get it at a lower price, but I think the trends in their businesses around the world are almost all in their favor. Exposure to Mexico is a big plus, in my opinion, but most of Cemex's business is actually outside their home country. I also do like, incidentally, Fomento Economico Mexicano (FMX) (AKA FEMSA) as another potential Mexican play on beer, Coke bottling, and convenience stores ... I'd prefer to look at a smaller cap company, but if those shares come down a little I'll be looking at them much more closely.
If you have any opinions about where I ought to be investing now, I'd love to hear them.
Labels: buy
This article posted by One Guy @ 4/04/2006 12:29:00 PM 0 comments
Add to: del.icio.us *Furl *Google *Spurl *reddit *StumbleUpon *Yahoo MyWeb *
Add to: del.icio.us *Furl *Google *Spurl *reddit *StumbleUpon *Yahoo MyWeb *
